{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T20:40:55Z","timestamp":1675197655781},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/pgp.0b013e3182297fd2","type":"journal-article","created":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T12:22:35Z","timestamp":1328703755000},"page":"125-132","source":"Crossref","is-referenced-by-count":15,"title":["Aberrant Expression of WWOX Protein in Epithelial Ovarian Cancer"],"prefix":"10.1097","volume":"31","author":[{"given":"Chao","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Chenggang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bu","family":"Yulan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deng","family":"Xiaohui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Junhui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20230131","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000197911","article-title":"Association between CpG islands methylation of the WWOX gene and its expression in breast cancers.","volume":"30","author":"Wang","year":"2009","journal-title":"Tumor Biol"},{"key":"R2-4-20230131","first-page":"2140","article-title":"WWOX, a novel domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.","volume":"60","author":"Bednark","year":"2000","journal-title":"Cancer Res"},{"key":"R3-4-20230131","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-004-1474-x","article-title":"Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status.","volume":"89","author":"Nunez","year":"2005","journal-title":"Breast cancer Res Treat"},{"key":"R4-4-20230131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2407-5-64","article-title":"WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome.","volume":"5","author":"Nunez","year":"2005","journal-title":"BMC Cancer"},{"key":"R5-4-20230131","first-page":"1681","article-title":"WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear.","volume":"26","author":"Gourley","year":"2005","journal-title":"Int J Oncol"},{"key":"R6-4-20230131","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-08-2974","article-title":"WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.","volume":"69","author":"Gourley","year":"2009","journal-title":"Cancer Res"},{"key":"R7-4-20230131","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/sj.onc.1208398","article-title":"Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.","volume":"24","author":"Iliopoulos","year":"2005","journal-title":"Oncogene"},{"key":"R8-4-20230131","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1158\/1078-0432.CCR-05-1551","article-title":"Prognostic DNA methylation biomarkers in ovarian cancer.","volume":"12","author":"Wei","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R9-4-20230131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network.","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R12-4-20230131","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: a review and proposal.","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"R13-4-20230131","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1440-1827.2005.01855.x","article-title":"Concordant loss of fragile gene expression early in breast cancer development.","volume":"55","author":"Guler","year":"2005","journal-title":"Pathol Int"},{"key":"R14-4-20230131","doi-asserted-by":"crossref","first-page":"775","DOI":"10.5858\/133.5.775","article-title":"Implementation of American Society of Clinical OncologyCollege of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.","volume":"133","author":"Middleton","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"R15-4-20230131","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical OncologyCollege of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"R16-4-20230131","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1525-1438.2006.00503.x","article-title":"Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy.","volume":"16","author":"Crijns","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"R17-4-20230131","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.20137","article-title":"The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.","volume":"100","author":"Guler","year":"2004","journal-title":"Cancer"},{"key":"R18-4-20230131","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1158\/1078-0432.CCR-07-1282","article-title":"Wwox and Ap2gamma expression levels predict tamoxifen response.","volume":"13","author":"Guler","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R19-4-20230131","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000086958","article-title":"HER2neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance.","volume":"68","author":"Verri","year":"2005","journal-title":"Oncology"},{"key":"R20-4-20230131","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2559.2005.02306.x","article-title":"HER-2neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.","volume":"48","author":"Mayr","year":"2006","journal-title":"Histopathology"},{"key":"R21-4-20230131","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.bjc.6604471","article-title":"The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.","volume":"99","author":"de Graeff","year":"2008","journal-title":"Br J Cancer"},{"key":"R22-4-20230131","doi-asserted-by":"crossref","first-page":"e1138","DOI":"10.1371\/journal.pone.0001138","article-title":"HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.","volume":"2","author":"Tuefferd","year":"2007","journal-title":"PLoS ONE"},{"key":"R23-4-20230131","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cncr.11476","article-title":"Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.","volume":"98","author":"Hogdall","year":"2003","journal-title":"Cancer"},{"key":"R24-4-20230131","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R26-4-20230131","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1447-0756.2007.00486.x","article-title":"Effect of HER-2neu overexpression on chemoresistance and prognosis in ovarian carcinoma.","volume":"33","author":"Sasaki","year":"2007","journal-title":"J Obstet Gynaecol Res"},{"key":"R27-4-20230131","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1541-7786.MCR-07-0211","article-title":"Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling.","volume":"5","author":"Qin","year":"2007","journal-title":"Mol Cancer Res"},{"key":"R28-4-20230131","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.24103","article-title":"Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2 gamma expression levels correlate with basal phenotype in breast cancer.","volume":"115","author":"Guler","year":"2009","journal-title":"Cancer"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004347-201203000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T20:11:53Z","timestamp":1675195913000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004347-201203000-00004"}},"subtitle":["A Clinicopathologic and Immunohistochemical Study"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0b013e3182297fd2","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}